Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-812-1 | CAS number: 593-84-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
In an acute oral toxicity study according to OECD guideline 401 with Guanidine Thiocyanate in Sprague Dawley rats, three groups of five fasted female animals were given a single oral dose of test material, in distilled water at dose levels of 354, 500 and 707 mg/kg bodyweight. A further group of five fasted males was similarly treated, at a dose level of 354 mg/kg bodyweight, to confirm that this sex was not markedly more sensitive to the test material. The surviving animals were observed for fourteen days after the day of dosing. All animals were subjected to gross pathological examination.
Oral LD50 Females = 593 mg/kg bw (95% C.I. 431 - 816)
Oral LD0 Males = 354 mg/kg bw
Deaths were noted during the day of dosing at 500 and 707 mg/kg bw. Clinical observations noted were ataxia, clonic convulsions, pallor of the extremities, hunched posture, lethargy, piloerection, ptosis, decreased respiratory rate, gasping, laboured and noisy respiration, increased salivation, staining around the mouth and snout and splayed or tiptoe gait. Surviving animals recovered one to three days after dosing except for male animals treated with 354 mg/kg which appeared normal throughout the study.
Surviving animals showed expected gain in bodyweight during the study.
Abnormalities noted at necropsy of animals that died during the study were haemorrhagic lungs, dark liver, dark kidneys and haemorrhagic gastric mucosa. No abnormalities were noted at necropsy of animals that were killed at the end of the study.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1998-03-04 to 1998-03-17
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd
- Age at sudy initation: 8 -12 weeks
- Weight at study initiation: Males: 201 to 212g; Females 201 to 225g
- Fasting period before study: Overnight
- Housing: In groups of up to five by sex in solid-floor polypropylene cages
- Diet (e.g. ad libitum): Rat and Mouse Expanded Diet No. 1, (Special Diets Services Limited, Witham, Essex UK), ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: minimum 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 23 °C
- Humidity (%): 50 - 60 %
- Air changes (per hr): 15/ hr
- Photoperiod (hrs dark / hrs light): twelve hour continuous light/dark cycle - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
-Concentration in vehicle: 35.4 mg/mL; 50 mg/mgl; 70.7 mg/mL
Amount of vehicle: 10 mL/kg - Doses:
- females: 354 mg/kg bw, 500 mg/kg bw, 707 mg/kg bw
males: 354 mg/kg bw - No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administation: 14 days
- Frequency of observations and weighing: 1/2, 1, 2 and 4 hours after dosing and subsequently once daily for fourteen days
- Necropsy of suvivors performed: Yes
- Other examinations performed: bodyweight, clinical signs - Statistics:
- Probit Analysis, the LD50 and 95 % confidence limits were calculated for females only.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 593 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 431 - 816
- Key result
- Sex:
- male
- Dose descriptor:
- LD0
- Effect level:
- 354 mg/kg bw
- Based on:
- test mat.
- Mortality:
- 0/5 males died 1 day after the administration (354 mg/kg bw)
0/5 females died 1 day after the administration (354 mg/kg bw)
3/5 females died 1 day after the administration (500 mg/kg bw)
3/5 females died 1 day after the administration (707 mg/kg bw) - Clinical signs:
- other: Clinical observations noted were ataxia, clonic convulsions, pallor of the extremities, hunched posture, lethargy, piloerection, ptosis, decreased respiratory rate, gasping, laboured and noisy respiration, increased salivation, staining around the mouth a
- Gross pathology:
- Abnormalities noted at necropsy of animals that died during the study were haemorrhagic lungs, dark liver, dark kidneys and haemorrhagic gastric mucosa. No abnormalities were noted at necropsy of animals that were killed at the end of the study.
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The LD50 value for Guanidine Thiocyanate was determined to be 593 mg/kg bw (95 % confidence interval 431 - 816 mg/kg bw in female animals.
Male animals were considered not to be markedly more sensitive to the test material than female animals. - Executive summary:
In an acute oral toxicity study according to OECD guideline 401 with Guanidine Thiocyanate in Sprague Dawley rats, three groups of five fasted female animals were given a single oral dose of test material, in distilled water at dose levels of 354, 500 and 707 mg/kg bodyweight. A further group of five fasted males was similarly treated, at a dose level of 354 mg/kg bodyweight, to confirm that this sex was not markedly more sensitive to the test material. The surviving animals were observed for fourteen days after the day of dosing. All animals were subjected to gross pathological examination.
Oral LD50 Females = 593 mg/kg bw (95% C.I. 431 - 816)
Oral LD0Males = 354 mg/kg bw
Deaths were noted during the day of dosing at 500 and 707 mg/kg bw. Clinical observations noted were ataxia, clonic convulsions, pallor of the extremities, hunched posture, lethargy, piloerection, ptosis, decreased respiratory rate, gasping, laboured and noisy respiration, increased salivation, staining around the mouth and snout and splayed or tiptoe gait. Surviving animals recovered one to three days after dosing except for male animals treated with 354 mg/kg which appeared normal throughout the study.
Surviving animals showed expected gain in bodyweight during the study.
Abnormalities noted at necropsy of animals that died during the study were haemorrhagic lungs, dark liver, dark kidneys and haemorrhagic gastric mucosa. No abnormalities were noted at necropsy of animals that were killed at the end of the study.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 354 mg/kg bw
- Quality of whole database:
- Data from a GLP compliant guideline study with reliability 1.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Based on the oral LD50 value of 593 mg/kg bw in female rats and the LD0 value of 354 mg/kg bw for acute oral toxicity Cat. 4 is required according to CLP (EU-GHS) Regulation (EC) No 1272/2008 for Guanidine Thiocyanate, which is consistent to legal binding C&L for acute toxicity Cat. 4 all routes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
